Open AccessP1005: A PHASE 1, OPEN‐LABEL, DOSE‐ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT‐NAÏVE MYELOFIBROSIS
Author(s) -
Ali H.,
Kishtagari A.,
Maher K.,
Mohan S.,
Mazumder A.,
Chamoun K.,
Karasik I.,
Sbar E.,
Dugom L.,
Tamir S.,
Wang X.,
Prchal J.,
Tantravahi S.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846888.40027.b8
Subject(s) - ruxolitinib , medicine , myelofibrosis , myeloproliferative neoplasm , phases of clinical research , nausea , oncology , maximum tolerated dose , plerixafor , refractory (planetary science) , myeloid , bone marrow , pharmacology , cancer , clinical trial , receptor , physics , chemokine , cxcr4 , astrobiology